Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Shweta Sharma, Shubham Srivastava, Apeksha Shrivastava, Ruchi Malik, Faisal Almalki, Khalid Saifullah, Mohammad Mumtaz Alam, Mohammad Shaqiquzzaman, Shakir Ali & Mymoona Akhter. (2020) Mining of potential dipeptidyl peptidase-IV inhibitors as anti-diabetic agents using integrated in silico approaches. Journal of Biomolecular Structure and Dynamics 38:18, pages 5349-5361.
Read now
Read now
Daisuke Yabe & Yutaka Seino. (2016) Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 15:2, pages 249-264.
Read now
Read now
Kohei Kaku. (2013)
Fasiglifam as a new potential treatment option for patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 14:18, pages 2591-2600.
Read now
Read now
Yutaka Seino, Tetsuya Fujita, Shinzo Hiroi, Masashi Hirayama & Kohei Kaku. (2011) Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Current Medical Research and Opinion 27:sup3, pages 21-29.
Read now
Read now
Yutaka Seino, Tetsuya Fujita, Shinzo Hiroi, Masashi Hirayama & Kohei Kaku. (2011) Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Current Medical Research and Opinion 27:9, pages 1781-1792.
Read now
Read now
Joan Khoo, Christopher K Rayner, Karen L Jones & Michael Horowitz. (2009) Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Therapeutics and Clinical Risk Management 5, pages 683-698.
Read now
Read now
Articles from other publishers (44)
Osama A. Mohammed. (2023) Alogliptin Exhibits Multifaceted Effects in Thioacetamide-insulted Rats: A Novel Approach to Combating Hepatic Inflammation and Fibrogenesis. Pathology - Research and Practice, pages 154833.
Crossref
Crossref
Badrud Duza Mohammad, Mirza Shahed Baig, Neeraj Bhandari, Falak A. Siddiqui, Sharuk L. Khan, Zubair Ahmad, Farhat S. Khan, Priti Tagde & Philippe Jeandet. (2022) Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents. Molecules 27:18, pages 6001.
Crossref
Crossref
Saideh Rajai-Daryasarei, Mohammad Hossein Gohari & Narges Mohammadi. (2021) Reactions involving aryl methyl ketone and molecular iodine: a powerful tool in the one-pot synthesis of heterocycles. New Journal of Chemistry 45:44, pages 20486-20518.
Crossref
Crossref
Min Wu, Qian‐Qian Li, Hong Zhang, Xiao‐Xue Zhu, Xiao‐Jiao Li, Ying Li, Hai‐Gang Sun & Yan‐Hua Ding. (2021) Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase‐4 Inhibitor: A Randomized, Double‐Blinded, Placebo‐Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus. Clinical Pharmacology in Drug Development 10:6, pages 660-668.
Crossref
Crossref
Somayyeh Heydari, Davood Habibi, Ali Reza Faraji, Hassan keypour & Masoumeh Mahmoudabadi. (2021) An overview on the progress and development on the palladium catalyzed direct cyanation. Inorganica Chimica Acta 514, pages 119956.
Crossref
Crossref
Deborah A. Chon, Rachael T. Oxman, Rashmi S. Mullur & Jane Eileen Weinreb. 2019. Endocrine Disorders in Kidney Disease. Endocrine Disorders in Kidney Disease
49
74
.
Ming-rong Zhu, Jie Zhou, Yi Jin, Li-Hui Gao, Ling Li, Jun-Ru Yang, Chun-Mei Lu, Qi Hua Zhao & Ming-jin Xie. (2018) A manganese-salen complex as dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. International Journal of Biological Macromolecules 120, pages 1232-1239.
Crossref
Crossref
Yang Liu, Xueting Yao, Ling Song, Hongzhong Liu, Qian Zhao, Ji Jiang, Gang Ni, Chongtie Shi, Xifeng Ma, Huimin Zhou, Dongyang Liu & Pei Hu. (2018) Metabolites characterization of a novel DPP-4 inhibitor, imigliptin in humans and rats using ultra-high performance liquid chromatography coupled with synapt high-resolution mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 157, pages 189-200.
Crossref
Crossref
Yuli Cai, Tianshu Zeng, Zhongyuan Wen & Lulu Chen. (2017) Ethnic Differences in Efficacy and Safety of Alogliptin: A Systematic Review and Meta-Analysis. Diabetes Therapy 9:1, pages 177-191.
Crossref
Crossref
N. A. Petunina, E. V. Goncharova & S. A. Potapova. (2017) CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN. Medical Council:3, pages 32-37.
Crossref
Crossref
Ming-jin Xie, Ming-rong Zhu, Chun-Mei Lu, Yi Jin, Li-Hui Gao, Ling Li, Jie Zhou, Fan-fang Li, Qi Hua Zhao, Hong-Ke Liu, Peter J. Sadler & Carlos Sanchez-Cano. (2017) Synthesis and characterization of oxidovanadium complexes as enzyme inhibitors targeting dipeptidyl peptidase IV. Journal of Inorganic Biochemistry 175, pages 29-35.
Crossref
Crossref
T. Biftu & R. SinhaRoy. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
512
555
.
Jifeng Deng, Jiayin Guo, Renke Dai, Guicheng Zhang & Hui Xie. (2016) Determination of a novel dipeptidyl peptidase IV inhibitor in monkey plasma by HPLC–MS/MS and its application in a pharmacokinetics study. Journal of Pharmaceutical and Biomedical Analysis 117, pages 99-103.
Crossref
Crossref
Enrique Z. Fisman & Alexander Tenenbaum. (2015) Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovascular Diabetology 14:1.
Crossref
Crossref
K. Kaku, K. Enya, R. Nakaya, T. Ohira & R. Matsuno. (2015)
Efficacy and safety of fasiglifam (
TAK
‐875), a
G
protein‐coupled receptor 40 agonist, in
J
apanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double‐blind, placebo‐controlled, phase
III
trial
. Diabetes, Obesity and Metabolism 17:7, pages 675-681.
Crossref
Crossref
Gillian M. Keating. (2015) Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 75:7, pages 777-796.
Crossref
Crossref
Toshiyuki Nakao, Masaaki Inaba, Masanori Abe, Kazo Kaizu, Kenji Shima, Tetsuya Babazono, Tadashi Tomo, Hideki Hirakata & Tadao Akizawa. (2015) Best Practice for Diabetic Patients on Hemodialysis 2012. Therapeutic Apheresis and Dialysis 19, pages 40-66.
Crossref
Crossref
Omprakash Tanwar, Lalima Tanwar, Md. Shaquiquzzaman, Md. Mumtaz Alam & Mymoona Akhter. (2014) Structure based virtual screening of MDPI database: Discovery of structurally diverse and novel DPP-IV inhibitors. Bioorganic & Medicinal Chemistry Letters 24:15, pages 3447-3451.
Crossref
Crossref
R. E. Pratley, P. Fleck & C. Wilson. (2014) Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes, Obesity and Metabolism 16:7, pages 613-621.
Crossref
Crossref
Yifei Zhang, Jie Hong, Jie Chi, Weiqiong Gu, Guang Ning & Weiqing Wang. (2014) Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes/Metabolism Research and Reviews 30:3, pages 241-256.
Crossref
Crossref
Uche Anadu NdefoOkwuchukwu OkoliGoldina Erowele. (2014) Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. American Journal of Health-System Pharmacy 71:2, pages 103-109.
Crossref
Crossref
Kouichi Inukai, Takumi Hirata, Takashi Sumita, Masaki Watanabe, Yuichi Ikegami, Daisuke Ito, Susumu Kurihara, Nobuyuki Yasukawa, Jiro Morimoto, Nobuki Takata, Kenta Kanazawa, Tamotsu Neda, Yoshikazu Sumitani, Kiyoaki Inoue, Yuichi Noguchi, Toshio Hosaka, Hitoshi Ishida & Shigehiro Katayama. (2014) Clinical Characteristics of Japanese Type 2 Diabetic Patients Responsive to Sitagliptin. Journal of Diabetes Mellitus 04:03, pages 172-178.
Crossref
Crossref
J. Rosenstock, C. Wilson & P. Fleck. (2013) Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes, Obesity and Metabolism 15:10, pages 906-914.
Crossref
Crossref
R Ito, Y Tsujihata, K Matsuda-Nagasumi, I Mori, N Negoro & K Takeuchi. (2013) TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats. British Journal of Pharmacology 170:3, pages 568-580.
Crossref
Crossref
Cui Wei, Liang Desheng, Gao Jian, Luo Fang, Geng Lingling & Ji Mingjuan. (2012) Molecular dynamics and free energy studies of chirality specificity effects on aminobenzo[a]quinolizine inhibitors binding to DPP-IV. Journal of Molecular Modeling 19:3, pages 1167-1177.
Crossref
Crossref
. (2013) . Nihon Toseki Igakkai Zasshi 46:3, pages 334-339.
Crossref
Crossref
Yutaka Seino, Shinzo Hiroi, Masashi Hirayama & Kohei Kaku. (2012) Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study. Journal of Diabetes Investigation 3:6, pages 517-525.
Crossref
Crossref
Sudhanshu Kumar Bharti, Supriya Krishnan, Amit Kumar, Kaushal Kishore Rajak, Krishna Murari, Binod Kumar Bharti & Ashok Kumar Gupta. (2012) Antihyperglycemic activity with DPP-IV inhibition of alkaloids from seed extract of Castanospermum australe: Investigation by experimental validation and molecular docking. Phytomedicine 20:1, pages 24-31.
Crossref
Crossref
Y. Seino, Y. Miyata, S. Hiroi, M. Hirayama & K. Kaku. (2012) Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study. Diabetes, Obesity and Metabolism 14:10, pages 927-936.
Crossref
Crossref
Larry K. Golightly, Caitlin C. Drayna & Michael T. McDermott. (2012) Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors. Clinical Pharmacokinetics 51:8, pages 501-514.
Crossref
Crossref
Bo Ahrén. (2011) DPP‐4 inhibition and islet function. Journal of Diabetes Investigation 3:1, pages 3-10.
Crossref
Crossref
Kohei Kaku, Masashi Hirayama & Emiko Komura. (2012) Alogliptin-Pioglitazone Combination Therapy: A Rational Approach to Treating Type 2 Diabetes Mellitus. Combination Products in Therapy 2:1.
Crossref
Crossref
K. Kaku, T. Itayasu, S. Hiroi, M. Hirayama & Y. Seino. (2011) Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes, Obesity and Metabolism 13:11, pages 1028-1035.
Crossref
Crossref
Wei Wang, Pratik Devasthale, Aiying Wang, Tom Harrity, Don Egan, Nathan Morgan, Michael Cap, Aberra Fura, Herbert E. Klei, Kevin Kish, Carolyn Weigelt, Lucy Sun, Paul Levesque, Yi-Xin Li, Robert Zahler, Mark S. Kirby & Lawrence G. Hamann. (2011) 7-Oxopyrrolopyridine-derived DPP4 inhibitors—mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site. Bioorganic & Medicinal Chemistry Letters 21:22, pages 6646-6651.
Crossref
Crossref
Roberta Baetta & Alberto Corsini. (2011) Pharmacology of Dipeptidyl Peptidase-4 Inhibitors. Drugs 71:11, pages 1441-1467.
Crossref
Crossref
Bo Ahrén. (2011) GLP-1 for type 2 diabetes. Experimental Cell Research 317:9, pages 1239-1245.
Crossref
Crossref
Sarah E. Poplawski, Jack H. Lai, David G. Sanford, James L. Sudmeier, Wengen Wu & William W. Bachovchin. (2011) Pro-Soft Val-boroPro: A Strategy for Enhancing in Vivo Performance of Boronic Acid Inhibitors of Serine Proteases. Journal of Medicinal Chemistry 54:7, pages 2022-2028.
Crossref
Crossref
Bo Ahrén. (2011) Are Sulfonylureas Less Desirable Than DPP-4 Inhibitors as Add-on to Metformin in the Treatment of Type 2 Diabetes?. Current Diabetes Reports 11:2, pages 83-90.
Crossref
Crossref
Yasufumi Miyamoto, Yoshihiro Banno, Tohru Yamashita, Tatsuhiko Fujimoto, Satoru Oi, Yusuke Moritoh, Tomoko Asakawa, Osamu Kataoka, Hiroaki Yashiro, Koji Takeuchi, Nobuhiro Suzuki, Koji Ikedo, Takuo Kosaka, Shigetoshi Tsubotani, Akiyoshi Tani, Masako Sasaki, Miyuki Funami, Michiko Amano, Yoshio Yamamoto, Kathleen Aertgeerts, Jason Yano & Hironobu Maezaki. (2011) Discovery of a 3-Pyridylacetic Acid Derivative (TAK-100) as a Potent, Selective and Orally Active Dipeptidyl Peptidase IV (DPP-4) Inhibitor. Journal of Medicinal Chemistry 54:3, pages 831-850.
Crossref
Crossref
Joanne Bronson, Murali Dhar, William Ewing & Nils Lonberg. 2011.
433
502
.
Fraser F. Fleming, Lihua Yao, P. C. Ravikumar, Lee Funk & Brian C. Shook. (2010) Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore. Journal of Medicinal Chemistry 53:22, pages 7902-7917.
Crossref
Crossref
Lesley J. Scott. (2010) Alogliptin. Drugs 70:15, pages 2051-2072.
Crossref
Crossref
André J. Scheen. (2010) Dipeptidylpeptitase-4 Inhibitors (Gliptins). Clinical Pharmacokinetics 49:9, pages 573-588.
Crossref
Crossref
A. J. Scheen. (2010) Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes, Obesity and Metabolism 12:8, pages 648-658.
Crossref
Crossref